Cart
sales@molnova.com
NL-1
CAS No. 188532-26-5
NL-1( —— )
Catalog No. M21575 CAS No. 188532-26-5
NL-1 is a mitoNEET inhibitor with antileukemic effect.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 39 | In Stock |
|
| 10MG | 58 | In Stock |
|
| 25MG | 120 | In Stock |
|
| 50MG | 201 | In Stock |
|
| 100MG | 301 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNL-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionNL-1 is a mitoNEET inhibitor with antileukemic effect.
-
DescriptionNL-1 is a mitoNEET inhibitor with antileukemic effect.
-
In VitroNL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 μM, 94.26 μM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 μM for NL-1. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells. Cell Proliferation Assay Cell Line:REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines Concentration:10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM Incubation Time:72 hours Result:Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner.Cell Autophagy Assay Cell Line:REH, REH/Ara-C cell lines Concentration:60 μM Incubation Time:6 hours Result:Induced cell autophagy.
-
In VivoNL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model. Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells Dosage:10 mg/kg Administration:Intraperitoneal injection; daily; for 5 days Result:Showed antileukemic activity in an in vivo mouse ALL model.
-
Synonyms——
-
PathwayAutophagy
-
TargetAutophagy
-
RecptormitoNEET
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number188532-26-5
-
Formula Weight335.46
-
Molecular FormulaC18H25NO3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (745.25 mM; Need ultrasonic)
-
SMILESCC(C)(C)c1cc(CC2SC(=O)NC2=O)cc(c1O)C(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Geldenhuys WJ et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34.
molnova catalog
related products
-
Succinylsulfathiazol...
Succinylsulfathiazole is a sulfonamide, it is an ultra long acting drug.
-
Mefloquine hydrochlo...
A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine; inhibits autophagy and has been recognized as a potential target for cancer therapy.
-
AUTEN-67
A small molecule autophagy enhancer that specificly inhibits myotubularin-related phosphatase MTMR14; at concentrations of 2, 10, and 100 uM, AUTEN-67 inhibits MTMR14 by nearly 3%, 25%, and 70%, respectively.
